Scholars Central

PerspectivePublished 21 Jul 2016

HIV drug policies and South markets: settling controversies

Authors: Daniele Dionisio, Claudio Fabbri, Daniela Messeri

Clinical Practice

Volume 5 · Issue 5 · Pages 707

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite progress, antiretroviral therapy coverage in low- and middle-income countries remains poor: only 31% of HIV-infected people in need were receiving treatment in 2007. Obstacles include weak healthcare systems, a critical shortage of human resources and a lack of sustainable, long-term funding. Considering that health spending is still less than US$10 per person per year in most African countries, these obstacles act as key barriers in preventing poor people from obtaining life-saving drugs. Under this backcloth, out-ofreach prices still prevent HIV-infected people in most income-constrained countries from accessing brand antiretroviral drugs (ARVs). In the meantime, evolutionary strategies by governments and generic companies in emerging South markets look like they would place a risk of failure on the ARVs pricing policies of the multinational brand corporations. This article explores an attuned model to allow the brand and generic manufacturers to appropriately tackle evolutionary trends in the emerging markets, while securing the poorest expanded access to fairly priced ARVs, either for the present or the future. The potential of the model was investigated by examining: the current brand and generic company roles; the forecasts from government and drug trading directions of India, China, USA, Canada, Brazil and Thailand; the foreseeable implications of multiplying South–South partnerships; and the impact of the UNITAID–Clinton Foundation coalition. The highlighted model aims to reliably provide – through a combination of incentives, the WHO’s brokerage, fairly used differential pricing and the World Trade Organization’s flexibilities – several opportunities to the brand and generic enterprises, while cutting prices and promoting equitable access to ARVs.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Daniele Dionisio”
  • BylineArticles whose byline prints “Claudio Fabbri”
  • BylineArticles whose byline prints “Daniela Messeri”